Nociceptive and inflammatory responses induced by formalin in the orofacial region of rats: Effect of anti-TNFα strategies

International Immunopharmacology

Volumn 9, Issue 1, 2009, Pages 80-85

  Seadi Pereira, Paula Juliana ^a   Noronha Dornelles, Fabiana ^a   Santiago Santos, Diógenes ^a   Batista Calixto, João ^b   Bueno Morrone, Fernanda ^a   Campos, Maria Martha ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Formalin; Nociception; Orofacial region; Plasma extravasation; Rat; TNF

Indexed keywords

FORMALDEHYDE; INFLIXIMAB; MONOCLONAL ANTIBODY; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; EXTRAVASATION; INFLAMMATION; INJECTION SITE; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; UPPER LIP;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BEHAVIOR, ANIMAL; CAPILLARY PERMEABILITY; FACIAL PAIN; FORMALDEHYDE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INJECTIONS; LIP; MALE; PAIN MEASUREMENT; RATS; RATS, WISTAR; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149463623     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.10.001     Document Type: Article

References (48)

1. Chichorro J.G., Lorenzetti B.B., and Zampronio A.R. Involvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin-induced orofacial nociception in rats. Br J Pharmacol 14 (2004) 1175-1184
2. Julius D., and Basaum A.I. Molecular mechanisms of nociception. Nature 413 (2001) 203-210
3. Le Bars D., Gozariu M., and Cadden S. Animal models of nociception. Pharmacol Rev 53 (2001) 597-652
4. Merskey H. Pain terms: a list with definitions and notes on usage. Recommended by the IASP subcommitee on Taxonomy. Pain 6 (1979) 249-252
5. Russo C.M., and Brose W.G. Chronic pain. Ann Rev Med 49 (1998) 123-133
6. Fürst S. Transmitters involved in antinociception in the spinal cord. Brain Res Bull 48 (1999) 129-141
7. Ashburn M.A., and Staats P.S. Management of chronic pain. Lancet 353 (1999) 1865-1869
8. Loeser J.D., and Melzack R. Pain: an overview. Lancet 353 (1999) 1607-1609
9. Loeser J.D. What's to be done? Comments on Grabow et al. Clin J Pain 19 (2003) 384
10. Skött O. Pain: new insights, new treatments?. Am J Physiol Regul Integr Comp Physiol 285 (2003) 30-31
11. Stein C., Schäefer M., and Machelska H. Attacking pain at its source: new perspectives on opioids. Nature Med 9 (2003) 1003-1008
12. Shinal R.M., and Fillingim. Overview of orofacial pain: epidemiology and gender differences in orofacial pain. Dent Clin North Am 51 (2007) 1-18
13. Wang Y., Zhou D., Shen Q., Cheng C., Liu H.O., Qin Y., et al. Lipopolysaccharide-induced upregulation of tumor necrosis factor-alpha (TNF-alpha) and TNF receptors in rat sciatic nerve. J Mol Neurosci 32 (2007) 207-216
14. Kardel R., Ulfgren A.K., Reinholt F.P., and Holmlund A. Inflammatory cell and cytokine patterns in patients with painful clicking and osteoarthritis in the temporomandibular joint. Int J Oral Maxillofac Surg 32 (2003) 390-396
15. Moen K., Kvalvik A.G., Hellem S., Jonsson R., and Brun J.G. The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endo 100 (2005) 433-440
16. Suryaprasad A.G., and Prindiville T. The biology of TNF blockade. Autoimmun Rev 2 (2003) 346-357
17. Choo-Kang B.S., Hutchison S., Nickdel M.B., Bundick R.V., Leishman A.J., Brewer J.M., et al. TNF-blocking therapies: an alternative mode of action?. Trends Immunol 26 (2005) 518-522
18. Feldmann M., Brennan F.M., Foxwell B.M., Taylor P.C., Williams R.O., and Maini R.N. Anti-TNF therapy: where have we got to in 2005?. J Autoimmun 25 (2005) 26-28
19. Choi H.S., Ju J.S., Lee H.J., Jung C.Y., Kim B.C., Park J.S., et al. Effects of Tnf-a injected intracisternally on the nociceptive jaw-opening reflex and orofacial formalin test in freely moving rats. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 613-618
20. Shafer D.M., Assael L., White L.B., and Rossomando E.F. Tumor necrosis factor-alpha as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements. J Oral Maxillofac Surg 52 (1994) 786-791
21. Emshoff R., Puffer P., Strobl H., and Gassner R. Effect of temporomandibular joint arthrocentesis on synovial fluid mediator level of tumor necrosis factor-alpha: implications for treatment outcome. Int J Oral Maxillofac Surg 29 (2000) 176-182
22. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110
23. Rodrigues G.B., Passos G.F., Di Giunta G., Figueiredo C.P., Rodrigues E.B., Grumman Jr. A., et al. Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. Exp Eye Res 84 (2007) 553-560
24. Dubuisson D., and Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4 (1977) 161-174
25. Clavelou P., Pajot J., Dallel R., and Raboisson P. Application of the formalin test to the study of orofacial pain in the rat. Neurosci Lett 103 (1989) 349-353
26. Raboisson P., and Dallel R. The orofacial formalin test. Neurosci Biobehav Rev 28 (2004) 219-226
27. Kidd B.L., Photiou A., and Inglis J.J. The role of inflammatory mediators on nociception and pain in arthritis. Novartis Found Symp 260 (2004) 122-133
28. Sommer C., and Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 361 (2004) 184-187
29. Rocha A.C., Fernandes E.S., Quintão N.L., Campos M.M., and Calixto J.B. Relevance of tumour necrosis factor-α for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. Br J Pharmacol 148 (2006) 688-695
30. Sobrin L., Kim E.C., Christen W., Papadaki T., Letko E., and Foster C.S. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 125 (2007) 895-900
31. Mease P. Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag 2 (2006) 389-400
32. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., et al. TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol 126 (2008) 121-136
33. Atzeni F., Doria A., Carrabba M., Turiel M., and Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 6 (2007) 529-536
34. Kopp S., Alstergren P., Ernestam S., Nordahl S., and Bratt J. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis. Scand J Rheumatol 35 (2006) 182-188
35. Benoliel R., Sharav Y., Tal M., and Eliav E. Management of chronic orofacial pain: today and tomorrow. Compend Contin Educ Dent 24 (2003) 909-920
36. Martorell-Calatayud L., García-Mira B., and Peñarrocha-Diago M. Orofacial pain management: an update. Med Oral 9 (2004) 293-299
37. Lewis M.A., Sankar V., De Laat A., and Benoliel R. Management of neuropathic orofacial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endo 103 (2007) (Suppl:S32.e1-24)
38. Inglis J.J., Nissim A., Lees D.M., Hunt S.P., Chernajovsky Y., and Kidd B.L. The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation. Arthritis Res Ther 7 (2005) R807-16
39. Fröde T.S., Souza G.E., and Calixto J.B. The modulatory role played by TNF-alpha and IL-1 beta in the inflammatory responses induced by carrageenan in the mouse model of pleurisy. Cytokine 13 (2001) 162-168
40. Triantafillidis J.K., Papalois A.E., Parasi A., Anagnostakis E., Burnazos S., Gikas A., et al. Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. World J Gastroenterol 11 (2005) 6843-6847
41. Keifer J.A., Guttridge D.C., Ashburner B.P., and Baldwin Jr. A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276 (2001) 22382-22387
42. Eleutherakis-Papaiakovou V., Bamias A., and Dimopoulos M.A. Thalidomide in cancer medicine. Ann Oncol 15 (2004) 1151-1160
43. Quintão N.L., Balz D., Santos A.R., Campos M.M., and Calixto J.B. Long-lasting neuropathic pain induced by brachial plexus injury in mice: role triggered by the pro-inflammatory cytokine, tumour necrosis factor alpha. Neuropharmacology 50 (2006) 614-620
44. Padi S.S., Naidu P.S., and Kulkarni S.K. Involvement of peripheral prostaglandins in formalin-induced nociceptive behaviours in the orofacial area of rats. Inflammopharmacology 14 (2006) 57-61
45. Mahadevan U., and Sandborn W.J. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 7 (2001) 38-42
46. Gaya D.R., Aitken S., Fennell J., Satsangi J., and Shand A.G. Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution. Gut 55 (2006) 1524-1525
47. Boettger M.K., Hensellek S., Richter F., Gajda M., Stöckigt R., von Banchet G.S., et al. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum 58 (2008) 2368-2378
48. Lin T., Li K., Zhang F.Y., Zhang Z.K., Light A.R., and Fu K.Y. Dissociation of spinal microglia morphological activation and peripheral inflammation in inflammatory pain models. J Neuroimmunol 192 (2007) 40-48